WUXI, China, Feb. 26, 2025 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan’s Pharmaceuticals […]
Tag: WuXi Biologics
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
SHANGHAI, Oct. 28, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield glutamine synthetase (GS)-knockout Chinese hamster […]
WuXi Biologics Included in Hang Seng ESG 50 Index
HONG KONG, Sept. 23, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ESG 50 […]
WuXi Biologics Effectively Completes First Scale-Up of Top-Productiveness Bioprocessing Platform WuXiUI™ in 2,000L GMP Production
WuXi Biologics Achieves Milestone in 2,000L Drug Substance Production WuXi Biologics, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), recently announced a significant achievement in biologics manufacturing. Through the utilization of its ultra-intensified fed-batch […]
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
Partnership leverages Medigene’s leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics’ unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™ Collaboration is a three-year and […]